We scan new podcasts and send you the top 5 insights daily.
Malina Fan spent months trying to get plasmids, then realized depositing scientists wanted to share but lacked time and infrastructure. Greg Crescenzi says Addgene took over storage, logistics, legal agreements, QC, and curation, removing the burden from both requesters and institutions shipping materials so sharing could scale.
When Mark Zuckerberg and Priscilla Chan proposed curing all disease, top scientists didn't cite scientific limits. Instead, they pointed to operational failures: data silos, unpublished information, and non-scalable tools. This revealed the core problem was engineering and infrastructure, not just pure science.
Greg Crescenzi says 90% of Addgene's COVID deposits and resources were made available to industry during the pandemic, enabling a faster collective response. Addgene now wants to extend that same industry access to much of its other translational material, not just crisis-specific reagents, according to him.
The biotech industry is held back because it lacks standardized, API-driven lab automation services akin to AWS for tech. Without this "cloud lab" infrastructure, each company must build its own from scratch, hindering progress and preventing the lean, rapid development seen in software.
Synthesizing a therapeutic molecule is insufficient for commercial success; the actual challenge is making medicine possible through rigorous regulatory and quality compliance. Thousands of small biotechs focus capital strictly on research pipelines and lack the capital to build expensive manufacturing facilities. Specialized CDMO partners provide the compliant infrastructure, specialized people, and end-to-end quality systems needed to advance molecules through clinical phases to approval.
Greg Crescenzi defines success as materials, methods, and even results flowing freely by default between academia and industry. Restricting access should be a conscious exception, he says. He also wants industry to share unpublished experiment information, including failures, because that knowledge is valuable to others.
At inception, seed-funded biotechs face a dilemma: buying specialized laboratory equipment leaves no budget for talent, while hiring scientists without instrumentation leaves them idle. Shared incubators resolve this capital allocation trap entirely by providing plug-and-play infrastructure immediately.
Greg Crescenzi says Addgene's Solid Bio deal brings a therapeutic company's technology to academic and industry labs. Addgene already sells NEB and Promega products and wants more such partnerships, making reagent sharing flow from industry to academia as well as the reverse, according to him.
Greg Crescenzi says Addgene has received over 15,000 CRISPR plasmid deposits, including foundational materials, and those have generated 300,000 shipments to 5,000 organizations. That shipment volume shows how a central repository prevents many labs from separately rebuilding the same validated tools and wasting time and money.
Greg Crescenzi says Addgene holds historical, curated information that no one else has and is talking with software and AI companies about partnerships. He sees AI today as rapidly changing the space and wants Addgene's archive to support new data and information products, he says.
Cell by Gene began as a tool to solve an internal data annotation bottleneck. By open-sourcing it, CZI unintentionally created a standard data format. The broader scientific community adopted the tool for its utility, organically creating a massive, shared cell atlas built by many contributors, not just CZI.